ClinicalBiostats

Clinical Trials

See the methods at work.

Statistical analyses of real clinical trials: design, endpoints, results and interpretation, organized by therapeutic area and linked to the methods behind them.

11,187 trials analyzed so far

Trials that use: Risk difference

New to this method? Read the tutorial →

6,276 results

VIOLETIndependent statistical analysis of A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 438NCT03562156
VIV-FIHIndependent statistical analysis of EasyCrossTM Device-Self-centering Catheter: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06412354).Phase NAResults postedn = 20NCT06412354
VIVID-1Independent statistical analysis of A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03926130).Phase 3Results postedn = 1,158NCT03926130
VOLVERIndependent statistical analysis of Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 167NCT04880785
VOYAGEIndependent statistical analysis of Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 244NCT02152956
VOYAGERIndependent statistical analysis of A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 31NCT00381810
VPCIndependent statistical analysis of Co-Design and Pilot Testing of Peer-led Community Outreach to Improve Equity, Veteran-Centeredness and Uptake of Lung Cancer Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 3NCT06389981
VRI01Independent statistical analysis of Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 92NCT02038842
Wait and SeeIndependent statistical analysis of Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 1,179NCT01202279
WAVEIndependent statistical analysis of Durvalumab Long-Term Safety and Efficacy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04078152).Phase 4Results postedn = 163NCT04078152
WEARIT-FRIndependent statistical analysis of LifeVest Safety and Efficacy in Real Life Settings in France: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03319160).Phase NAResults postedn = 1,164NCT03319160
WH-PACTIndependent statistical analysis of Implementation of Women's Health Patient Aligned Care Teams: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02039856).Phase NAResults postedn = 3,900NCT02039856
WHISPERIndependent statistical analysis of Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 229NCT02314000
WI223281Independent statistical analysis of Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 17NCT03535506
Willow 3Independent statistical analysis of A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04194892).Phase 1Results postedn = 12NCT04194892
WISARDIndependent statistical analysis of Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With…Phase 3Results postedn = 140NCT05349838
WISEIndependent statistical analysis of Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 120NCT01783639
X-TOLEIndependent statistical analysis of A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 325NCT03796962
X-TRAPIndependent statistical analysis of Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 63NCT01661972
XEPADIndependent statistical analysis of An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 274NCT01725386
YOGAMAT-IIIndependent statistical analysis of Optimization and Multi-Site Feasibility of Yoga for Chronic Pain in People in YOGAMAT-II - Phase II: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 192NCT04641221
ZEAL UNLOCKIndependent statistical analysis of A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 73NCT06269484
ZENITHIndependent statistical analysis of A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH): primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 173NCT04896008
ZEUSIndependent statistical analysis of Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2/3Results postedn = 465NCT02753946
ZODIACIndependent statistical analysis of OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 1,139NCT05844566
ZUMA-1Independent statistical analysis of Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1/2Results postedn = 307NCT02348216